Navigation Links
OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock
Date:11/5/2009

FORT WORTH, Texas, Nov. 5 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (WNDM), announced today that it has entered into a Letter of Intent to purchase all healthcare-related assets of Virtual Health Technologies, Inc. (OTC Bulletin Board: VHGI). The deal provides for VHGI to be paid $1,000,000 in cash and debt, 4,000,000 shares of WNDM and a royalty agreement for revenues generated by WNDM on the Veriscrip technology being acquired from VHGI. WNDM closed at $2.00 per share on 11/4/09 and VHGI closed at $0.27 per share on 11/4/09.

"WNDM will be acquiring Medical Office Software, Inc. (MOS), Secure eHealth, LLC, and the Veriscrip technology from Virtual Health Technologies, Inc.," stated Scott Haire, CEO of WNDM. "These businesses fit well with WNDM's domestic plans to leverage its existing infrastructure to develop opportunities within the Healthcare marketplace, and focus on the U.S. Government healthcare technology Initiative. We are confident that this will add tremendously to our bottom line. WNDM will continue to target major pharmaceutical companies from both a wound care product perspective as well as a medical technology company, and focus on increasing revenues and maximizing shareholder value."

"WNDM will be able to significantly expand its product distribution throughout various medical facilities with the acquisition of an established client base of approximately 1,500 doctors throughout the US currently using our technology. In addition many of these physicians have ongoing relationships with nursing homes which necessitate a need for improved wound care technology. This acquisition translates into the potential for significant increased sales for WNDM's core wound care product line," stated Ken Barnes, President of Medical Office Software.

Debbie Jenkins, Board member of VHGI, states, "As we continue to work with e-health we realize VHGI's technology plus WNDM's core sales and development ne
'/>"/>

SOURCE Wound Management Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS
2. Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas
3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
4. Microfluidics International Corporation Announces Third Quarter 2009 Financial Results
5. Oncothyreon announces webcast of third quarter 2009 financial results conference call
6. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
7. Osteotech Announces Third Quarter 2009 Financial Results Release and Conference Call
8. Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
9. BMP Sunstone Announces November Investor Conference Participation
10. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Israel Biomedical Sensors Market - Growth, Trends ... The Israel Biomedical Sensors market is estimated ... 3.73% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/31/2015)... , Aug. 31, 2015  For people with Down ... their day. The biotechnology company, located in the Science ... of the best potential therapies yet for people with Down ... " Correction of Down syndrome and Edwards syndrome aneuploidies ... DNA Research . Elixirgen plans to develop this ...
(Date:8/31/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... period following the filing of the Company,s Investigational ... U.S. Food and Drug Administration (FDA) has passed ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... and SHANGHAI , Aug. 31, ... company developing next-generation antibiotics, today announced positive top-line ... for its lead drug candidate MRX-I. MRX-I is ... bacteria such as MRSA and VRE, while offering ... therapeutic option than currently available oxazolidinone agents. ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2New Down syndrome therapy discovered 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... Quarter-to-Quarter Revenue Gain Evidences Start of Turnaround ... for Core Business ... Agreements, IRVING, Texas, Aug. 14 Carrington,Laboratories, Inc. (Nasdaq: CARN ) reported ... in the year ago,period. The revenue in the quarter just ended, while 17 percent ...
... Summertime equals fun for a lot of,folks. ... (IBS), typical,summer fare could also mean aggravating their ... for IBS," has more on,what people with IBS ... IBS from,ruining their celebrations. Listen to this ...
... Medical,Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... and markets advanced in-,vitro diagnostic products and high ... it will participate in the Morgan,Stanley,s 2007 China ... Date: August 21, 2007 China Medical Technologies, ...
Cached Biology Technology:Carrington Reports Second Quarter 2007 Results 2Carrington Reports Second Quarter 2007 Results 3Carrington Reports Second Quarter 2007 Results 4Carrington Reports Second Quarter 2007 Results 5Carrington Reports Second Quarter 2007 Results 6Carrington Reports Second Quarter 2007 Results 7
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... de 2015 La 10 th International Conference ... de BGI del 22 al 25 de octubre de 2015 en ... año, la conferencia celebra su décimo aniversario. Desde su inauguración ... de las reuniones anuales más influyentes del mundo en el ... dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... release is available in French . ... and dosage of antipsychotics may influence their efficacy, reported Philippe ... mentale de Montral and Universit de Montral. The efficacy of ... get into the bloodstream after being absorbed. Vincent and Kouassi ...
... healthy and then we weaken and die - that,s probably how ... the phenomenon of ageing shows an unexpected diversity of patterns and ... Denmark. Not all species weaken and become more likely ... likely to die with age, while others are not affected by ...
... The Children,s Hospital of Philadelphia have manipulated key biological ... of hemoglobin normally absent after the newborn period. Because ... in sickle cell disease (SCD), the cell culture findings ... the debilitating blood disorder. "Our study shows ...
Cached Biology News:How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy? 2Surprising diversity in aging revealed in nature 2Surprising diversity in aging revealed in nature 3Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease 2
Mouse Laminin-1 MAb (Clone AL-3)...
IEX-1 S/L (H-20)...
... reactivity with rat (100%), mouse ... pig (48%). Slight reactivity ... confirmed by Western blot versus ... Gia-1, Gia-2, rat Gia-3, bovine ...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
Biology Products: